GeneDx is trading 5% lower at $65.14, with the specific reason for the decline unconfirmed.
- No verified GeneDx announcement on October 8 explains the decline; its October 7 newborn-screening research and product news do not establish a negative company catalyst.
- Broader markets are under pressure amid rising Treasury yields, higher oil prices, and inflation and interest-rate concerns. This backdrop may be contributing, but the provided index moves are below the stated 0.5% threshold.